Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Innocan Pharma Corp C.INNO

Alternate Symbol(s):  INNPF

Innocan Pharma Corporation is an Israel-based company active in the pharmaceuticals and wellness sectors. In the pharmaceuticals sector, the Company aims to provide a safe, non-opioid chronic pain management solutions for both animals and humans. To achieve this aim, the Company developed a CBD-loaded liposome drug delivery platform with exact dosing, prolonged and controlled release of... see more

Recent & Breaking News (CSE:INNO)

Innocan Pharma Signs a First Consulting Agreement to Commercialize its Pharmaceutical IP in the Veterinary Field

Newsfile December 2, 2022

Innocan Pharma (CSE:INNO) reports Q3 2022 results

John Ballem  November 29, 2022

Innocan Pharma Reports Q3 2022 Results with 700% Increase in Revenues Compared to Q3 2021

Newsfile November 29, 2022

Mr. Givi Topchishvili to Join Innocan Pharma's Advisory Committee

Newsfile November 18, 2022

Canadian Securities Exchange Reports October 2022 Performance Figures

Newsfile November 15, 2022

Innocan Pharma Goes Live with Priority(TM) ERP System

Newsfile November 9, 2022

Innocan Pharma to Participate in IR Labs' Investor Webinar on November 2, 2022

Newsfile October 25, 2022

Innocan Pharma to Participate in the Luxury Meets CBD Conference on October 20 & 21 in New York

Newsfile October 13, 2022

Innocan Pharma (CSE:INNO) patent application for treatment of psoriasis of the scalp goes national

Jonathon Brown October 6, 2022

Innocan Pharma's Patent Application for Treatment of Psoriasis of the Scalp Reached National Phase

Newsfile October 6, 2022

Innocan Pharma (CSE:INNO) provides operational update

Sabrina Cuthbert September 21, 2022

Innocan Pharma Provides an Operational Update

Newsfile September 21, 2022

Innocan Pharma (CSE:INNO) reports another successful result from a pre-clinical study using LPT CBD Liposomal Delivery Platform

John Ballem  September 9, 2022

Innocan Pharma Reports Another Successful Result from a Pre-Clinical Study on a Dog Suffering from Refractory (Drug-Resistant) Epilepsy Following LPT Treatment

Newsfile September 9, 2022

Innocan Pharma to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

Newsfile September 6, 2022

Innocan Pharma Announces Q2 2022 Results with 70% Annual Increase in Cash Balance and 70% Increase in Working Capital

Newsfile August 30, 2022

Innocan Pharma (CSE:INNO) reports positive results in pilot pain study using LPT CBD Liposomal Delivery Platform

John Ballem  August 17, 2022

Innocan Pharma Meets Pre-Clinical End-Point in Pilot Pain Study on Dogs Using LPT Liposome Technology

Newsfile August 17, 2022

Innocan Pharma (CSE:INNO) approaches 100 per cent CBD bioavailability for its LPT CBD liposomal delivery platform

Azuka Onwuka August 11, 2022

Innocan Pharma Is Reaching Close to 100% CBD Bioavailability In a Dog Clinical Study For its Proprietary LPT CBD Liposomal Delivery Platform

Newsfile August 11, 2022